Forty-Third Board Meeting

Loading...
Date
YYYY-MM-DD
Board Meeting Decision Point Number Title
2020-05-14 B43 GF/B43/DP01 Appointment of the Rapporteur Appointment of the Rapporteur
<p>Ambassador Stéphanie Seydoux from the France constituency is designated as Rapporteur for the 43rd Board Meeting.</p>
2020-05-14 B43 GF/B43/DP02 Approval of the Agenda Approval of the Agenda
<p>The agenda for the 43rd Board Meeting (GF/B43/01) is approved.</p>
2020-05-15 B43 GF/B43/DP03 Approval of the Terms of Reference of the Inspector General Nomination Committee and revisions to the Terms of Reference of the Inspector General Approval of the Terms of Reference of the Inspector General Nomination Committee and revisions to the Terms of Reference of the Inspector General
<p>The Board:</p> <ol> <li>Notes its responsibilities with regard to the recruitment process of the Inspector General as set out in Article 36 of the Operating Procedures of the Board and Committees of the Global Fund to Fight AIDS, Tuberculosis and Malaria;</li> <li>Based on the recommendation of the Chair and Vice-Chair of the Board (the “Board Leadership”), in consultation with the Ethics and Governance Committee, and its review of the contents of GF/B43/12 – Revision 1 approves: <ol type="a"> <li>The terms of reference of the 2020 Inspector General Nomination Committee, as set out in Annex 1 to GF/B43/12 – Revision 1; and,</li> <li>The revised terms of reference of the Inspector General, as presented in Annex 2 to GF/B43/12 – Revision 1, which shall enter into force upon the commencement of the term of the next Inspector General.</li> </ol> </li> <li>Requests the Board Leadership to submit a Chair, Vice-Chair and the membership of the nomination committee to the Board for approval.</li> </ol>
2020-06-22 B43 GF/B43/EDP01 Decision on the Secretariat’s Recommendation on Additional Funding to Finance Unfunded Quality Demand from the 2017-2019 Allocation Period Decision on the Secretariat’s Recommendation on Additional Funding to Finance Unfunded Quality Demand from the 2017-2019 Allocation Period
<p>The Board:</p> <ol> <li>Approves the revised budget recommended for each grant listed in Table 1 of GF/B43/ER01 (“Table 1”);</li> <li>Affirms the additional funding approved under this decision (a) increases the upper-ceiling amount that may be available for the relevant implementation period of each country disease component’s constituent grants, and (b) is subject to the availability of funding; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP. </li> </ol>
2020-06-24 B43 GF/B43/EDP02 Appointment of Independent Committee Members of the Standing Committees of the Board Appointment of Independent Committee Members of the Standing Committees of the Board
<ol> <li>The Board approves the appointment of the following individuals to serve as non-voting independent members of the Audit and Finance Committee (the “AFC”) listed below, in the areas of expertise listed by their name: <ol type="i"> <li>Robert Samels, financial audit; and</li> <li>Diana Isiye, forensic investigation.</li> </ol> </li> <li>The Board approves the appointment of the following individual to serve as non-voting independent member of the Ethics and Governance Committee (the “EGC”) listed below, in the area of expertise listed by his name: <ol type="i"> <li>Mohammad Ali Mubarak Kisubi, ethics.</li> </ol> </li> <li>The Board notes each independent committee member appointed under this decision point is entitled to receive honoraria in accordance with the Global Fund’s Honorarium Framework.</li> <li>The Board notes each independent committee members appointed under this decision point shall begin their term on 24 June 2020 and serve for two years or until the appointment of their respective successors.</li> </ol> <p> </p>
2020-06-25 B43 GF/B43/EDP04 Amended and Restated Policy on Conflict of Interest Amended and Restated Policy on Conflict of Interest
<ol> <li class="x_MsoNormal">Based on the recommendation of the Ethics and Governance Committee (GF/EGC12/EDP02), the Board approves the amended and restated Policy on Conflict of Interest, as set forth in Annex 1 to GF/B43/ER04;</li> <li class="x_MsoNormal"><span></span>Accordingly, the Board acknowledges that this decision point and the amended and restated Policy on Conflict of Interest shall supersede the decision point GF/B27/DP05, the previous Policy on Ethics and Conflicts of Interest for Global Fund Institutions as set forth in Annex 1 to GF/B27/07 and the previous Declaration of Interest Form set forth in Annex 2 to GF/B27/07.</li> </ol>
2020-06-25 B43 GF/B43/EDP05 Amended and Restated Code of Conduct for Governance Officials Amended and Restated Code of Conduct for Governance Officials
<ol start="1" type="1"> <li class="x_MsoListParagraphCxSpLast"><span>Based on the recommendation of the Ethics and Governance Committee (GF/EGC12/EDP01), the Board approves the revisions to the Code of Conduct for Governance Officials, as set forth in Annex 1 and 2 to GF/B43/ER05, developed in furtherance of the Ethics and Integrity Framework adopted by the Board at its 32nd Meeting (GF/B32/DP09);</span></li> <li class="x_MsoListParagraphCxSpLast">Accordingly, the Board acknowledges that this decision point and the revisions to the Code of Conduct for Governance Officials shall supersede the approval of the previous Code of Ethical Conduct for Governance Officials, as set forth in Annex A to GF/B33/15 – Revision 2, pursuant to paragraph 2 of the decision point GF/B33/DP10.</li> </ol>
2020-06-30 B43 GF/B43/EDP06 Indicator Revisions and Target Setting for Key Performance Indicators 6a: Resilient and Sustainable Systems for Health: - Procurement; 6f: Alignment with National Strategic Plans; 9C: Key populations and human rights domestic investments and 12b: Availability of affordable health technologies: Affordability Indicator Revisions and Target Setting for Key Performance Indicators 6a: Resilient and Sustainable Systems for Health: - Procurement; 6f: Alignment with National Strategic Plans; 9C: Key populations and human rights domestic investments and 12b: Availability of affordable health technologies: Affordability
<ol> <li>Based on the recommendation of the Strategy Committee, the Board approves: <ol type="a"> <li>the revisions for Key Performance Indicator 6a as presented in GF/B43/ER06;</li> <li>the performance target for Key Performance Indicator 6f as presented in GF/B43/ER06; and</li> <li>the revisions for Key Performance Indicator 9c as presented in GF/B43/ER06.</li> </ol> </li> <li>Based on the recommendation of the Audit and Finance Committee, the Board approves the revision to the 2020 performance target for Key Performance Indicator 12b as presented in GF/B43/ER06.</li> </ol>
2020-07-07 B43 GF/B43/EDP07 Extending the wambo.org pilot to include COVID-19 products Extending the wambo.org pilot to include COVID-19 products
<ol> <ol> <li>The Board recognizes that the COVID-19 pandemic remains a global public health emergency and that failure to control the pandemic threatens to derail the Global Fund’s mission to fight HIV/AIDS, tuberculosis, and malaria and to strengthen systems for health. The Board further recognizes the importance of ensuring rapid availability of quality COVID-19 products as part of the global response to COVID-19, and the significant benefits that beneficiaries in Global Fund-eligible and transitioned countries could potentially gain from improved access to pooled procurement volumes of these products.</li> <li>The Board notes the Secretariat is engaging with partners, notably WHO, UNICEF, UNITAID, GDF, FIND, Africa CDC and the newly-created Africa Medical Supply Platform, and taking an active role in the ACT-A partnership and the Diagnostics Consortium, to ensure collaboration, coherence and flexibility in providing procurement options and solutions for countries to address the challenges of managing supply constraints and access to quality health products in the context of COVID-19. In this rapidly evolving context, the Board wishes to leverage wambo.org, and the pilot for non-Global Fund-financed transactions as defined in GF/B42/DP05 (the Pilot) to facilitate broader access to COVID-19 product.</li> <li>The Board notes that the Secretariat is using the wambo.org platform to facilitate the procurement of certain COVID-19 products purchased by Global Fund Principal Recipients. The Board further notes that the framework of eligibility and quality assurance defined in GF/B42/EDP11 for COVID-19 products is being proposed to apply to products available to all eligible buyers on wambo.org.</li> <li>In order to allow broader access to these products, as presented in GF/B43/ER07, the Board decides to formally extend the scope of the Pilot to include for eligible buyers as defined in GF/B42/DP05, the purchase of all COVID-19 products available in wambo.org for procurement by Global Fund Principal Recipients.</li> <li>Such non-Global Fund-financed transactions for COVID-19 products will:<br />- be individually subject to agreement by the Global Fund and, if applicable, to agreement by the product catalogue owners or manufacturers; <br />- not count towards the cap of USD 50 million of transactions for the Pilot otherwise applicable to non-COVID-19 products;<br />- be issued as Purchase Orders by wambo.org within the period ending in 31 December 2020, unless extended by the Board following recommendation by the Strategy Committee.</li> <li>As with the Pilot, use of the wambo.org platform for non-Global Fund-financed transactions will remain optional for eligible buyers of COVID-19 products.</li> <li>Recognizing the extraordinary conditions due to the COVID-19 pandemic under which non-Global Fund-financed transactions for COVID-19 products will be processed, and the importance of maintaining the integrity of the Pilot as currently established, the Board further decides:<br />a. reporting of transactions for COVID-19 products will be included in the biannual reporting on the Pilot to the Strategy Committee, following the same principles as other transactions, in particular with respect to the determination of metrics for reporting, which will be agreed by the Strategy Committee in October 2020. However, COVID-19 product transactions will be disaggregated from reporting on other Pilot transactions, so as to enable integration with overall reporting on the COVID-19 response, and to avoid distorting reporting on the original Pilot.<br />b. these COVID-19 transactions, disaggregated from other Pilot transactions, will be included in the final independent evaluation of the Pilot, to be delivered no later than end of 2022.<br />c. with the Strategy Committee, to resume broader discussions of wambo.org’s future strategy for the Pilot and its role and market influence within the development of the Phase 2 of the Market Shaping Strategy and the next Global Fund Strategy in 2020-2021.</li> </ol> </ol>
2020-07-28 B43 GF/B43/EDP08 Approval of the Report of the 43rd Board Meeting Approval of the Report of the 43rd Board Meeting
<p class="x_MsoNormal"><span>The Board approves the Report of the 43<sup>rd</sup> Board Meeting, as set forth in GF/B43/13.</span></p>
2020-08-06 B43 GF/B43/EDP09 Secretariat Appointment Secretariat Appointment
<p>The Board hereby notes the Executive Director’s appointment of the following senior management official of the Global Fund:</p> <ol type="i"> <li>Adda Faye, as Chief Financial Officer.</li> </ol>
2020-08-03 B43 GF/B43/EDP10 Appointment of the Inspector General Nomination Committee Membership Appointment of the Inspector General Nomination Committee Membership
<p>The Board appoints the following individuals to serve as members of the Inspector General Nomination Committee (Nomination Committee) in accordance with the terms of reference of the Nomination Committee approved under decision point GF/B43/DP03 and set out in Annex 1 to GF/B43/12 – Revision 1:</p> <ul> <li>Grace Rwakarema, Chair</li> <li>Thomas Alexander, Vice-Chair</li> <li>Allan Maleche, Member;</li> <li>Thomas Morrow, Member;</li> <li>David Webb, Member;</li> <li>Diana Isiye; Independent Member and,</li> <li>Norbert Hauser, Independent Member.</li> </ul>
2020-08-25 B43 GF/B43/EDP11 Extension of terms of the Board Chair and Vice-Chair Extension of terms of the Board Chair and Vice-Chair
<p>In response to the exceptional circumstances related to the current Covid-19 pandemic, the Board:</p> <ol> <li>Extends its recognition to Dr Donald Kaberuka, Chair of the Board, and Lady Roslyn Morauta, Vice-Chair of the Board, for their service since May 2019;</li> <li>Thanks the Ethics and Governance Committee for their recommendation and notes the analysis and review process preceding this decision; and</li> <li>Extends the terms of Dr Donald Kaberuka, as Chair of the Board, and Lady Roslyn Morauta, as Vice-Chair of the Board, to the adjournment of the first Board Meeting in 2022.</li> </ol>
2020-09-30 B43 GF/B43/EDP12 Extension of C19RM Timeline and Operational Flexibility for COVID-19 Extension of C19RM Timeline and Operational Flexibility for COVID-19
<p>The Board agrees that COVID-19 continues to pose a grave threat to the Global Fund’s mission to fight HIV/AIDS, tuberculosis, and malaria and strengthen systems for health, and that continued support for country responses to COVID-19 is critical to safeguard Global Fund programs and country health systems. The Board acknowledges its previous decisions establishing the Global Fund COVID-19 Response Mechanism (C19RM) to provide additional support for country responses to COVID-19 (GF/B42/EDP11), and approving certain time-bound operational flexibilities to ensure the continued delivery of the Global Fund mission during the pandemic (GF/B42/EDP10). Noting that COVID-19 continues to jeopardize country health systems and impede progress in the Global Fund’s mission, and that additional funds may become available for C19RM, the Board:</p> <ol> <li>Approves that the Secretariat may approve requests for C19RM funds through 15 April 2021;</li> <li>Affirms that all other previously approved principles under GF/B42/EDP11 will continue to apply to C19RM;</li> <li>Requests the Secretariat to return to the Board, through its Committees as relevant, for additional consideration and approval should further extensions of C19RM be required as the pandemic continues to evolve, or if total additional funding for C19RM exceeds USD 500 million; and</li> <li>Approves that the operational flexibility under paragraph 3 of GF/B42/EDP10, delegating authority to the Secretariat to grant limited exceptions to the Quality Assurance Policies to waive the requirement for pre-shipment sampling and testing for Expert Review Panel-approved products, vector control products, and condoms, where such testing may delay the delivery of products to countries, will apply through 15 April 2021.</li> </ol>
2020-10-05 B43 GF/B43/EDP13 Appointment of two Replacement Members on the Audit and Finance Committee, and one Replacement Member on the Ethics and Governance Committee Appointment of two Replacement Members on the Audit and Finance Committee, and one Replacement Member on the Ethics and Governance Committee
<ol> <li>The Board approves the appointment of Ms Shirley Carruthers, representing the Canada, Switzerland and Australia Constituency, as a voting member of the Audit and Finance Committee for a term that will expire in May 2022, or until the appointment of her successor.</li> <li>The Board approves the appointment of Mr Chimi Dorji, representing the South East Asia Constituency, as a voting member of the Audit and Finance Committee for a term that will expire in May 2022, or until the appointment of his successor.</li> <li>The Board approves the appointment of Ms Nathalie Olijslager, representing the Point Seven Constituency, as a voting member of the Ethics and Governance Committee for a term that will expire in May 2022, or until the appointment of her successor.</li> </ol>
2020-10-21 B43 GF/B43/EDP14 Decision on the Secretariat’s Recommendation on Funding from the 2020-2022 Allocation Decision on the Secretariat’s Recommendation on Funding from the 2020-2022 Allocation
<p>The Board:</p> <ol> <li>Approves the funding recommended for each country disease component, and its constituent grants, as listed in Table 1 of GF/B43/ER14 (“Table 1”);</li> <li>Acknowledges each country disease component’s constituent grants will be implemented by the proposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;</li> <li>Affirms the funding approved under this decision (a) is subject to the availability of funding, and (b) shall be committed in annual tranches; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol>
2020-10-22 B43 GF/B43/EDP15 Decision on Inspector General, contractual negotiations Decision on Inspector General, contractual negotiations
<p class="p1">The Board</p> <p class="p1">Mandates the Chair of the Board and the Vice-Chair of the Board, acting jointly</p> <ol class="ol1"> <li class="li2">to negotiate the terms of an employment agreement with each of the final candidates identified by the Inspector General Nomination Committee for the position of Inspector General</li> <li class="li2">to execute on behalf of the Global Fund the employment agreement with the Inspector General ultimately appointed by the Board, and</li> <li class="li2">to set the annual salary of the Inspector General within the salary scale applicable for the position of Inspector General, as set out in the Amended and Restated Global Fund Human Resources Policy Framework.</li> </ol>
2020-10-28 B43 GF/B43/EDP16 Approval of Additional Funding to Address the Health Crisis in Venezuela Approval of Additional Funding to Address the Health Crisis in Venezuela
<p>The Board:</p> <ol> <li>Expresses continuing concern about the public health crisis in Venezuela, a country that has been made eligible for Global Fund funding for malaria only for the 2020-2022 allocation period, under GF/B41/EDP06, and its adverse impact on the fight against HIV, tuberculosis and malaria in Venezuela and the region;</li> <li>Acknowledges the new proposal for exceptional funding in 2021 presented by the Secretariat, and developed in consultation with partners and civil society, in accordance with the approach for potential engagement with non-eligible countries in crisis approved by the Board through GF/B39/DP04;</li> <li>Recognizes that the emergency circumstances in Venezuela continue to require unique implementation and management arrangements, which differ substantially from the standard Global Fund funding model and applicable policies, as described in GF/B44/ER16 and Annex 1;</li> <li>Accepts that the proposed implementation and management arrangements continue to entail unique risks, as described in GF/B44/ER16 and Annex 1, including that the Office of the Inspector General will not be able to provide the Board with assurance, whether through audit or investigation work, over the funds disbursed under the proposed funding arrangements and that civil society oversight may not be able to provide adequate assurance as envisaged in GF/B44/ER16 and Annex 1;</li> <li>Based on the recommendation of the Strategy Committee, approves the investment and terms set forth in Annex 1, to provide an additional US$ 6,000,000, for the year 2021, to support the procurement of critical HIV &amp; TB health products for Venezuela and social monitoring of the investment; and</li> <li>Calls for continuous engagement from relevant partners, donors and other stakeholders to further support a regional response to the health crisis in Venezuela.</li> </ol>
2020-10-30 B43 GF/B43/EDP17 Decision on extending the timeline for including COVID-19 products in the wambo.org pilot Decision on extending the timeline for including COVID-19 products in the wambo.org pilot
<p>The Board:</p> <ol> <li>Recalls GF/B43/EDP07 where it decided to extend the scope of the wambo.org pilot to allow for eligible buyers, as defined in GF/B42/DP05, to purchase all COVID-19 products available in wambo.org for procurement by Global Fund Principal Recipients and specified that such non-Global Fund financed transactions for COVID-19 products will be issued as purchase orders by wambo.org within the period ending 31 December 2020, unless extended by the Board following a recommendation by the Strategy Committee; and</li> <li>Based on the recommendation of the Strategy Committee (GF/SC14/DP05), the Board approves the change in the end date of such period through which non-Global Fund financed transactions for COVID-19 products may be issued as purchase orders by wambo.org to 31 May 2021 and confirms that all other conditions and flexibilities set forth in GF/B43/EDP07 shall continue to apply.</li> </ol>
2020-11-06 B43 GF/B43/EDP18 Decision on the Secretariat’s Recommendation on Funding from the 2020-2022 Allocation Decision on the Secretariat’s Recommendation on Funding from the 2020-2022 Allocation
<p>The Board:</p> <ol> <li>Approves the funding recommended for each country disease component, and its constituent grants, as listed in Table 1 of GF/B43/ER18 (“Table 1”);</li> <li>Acknowledges each country disease component’s constituent grants will be implemented by the proposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;</li> <li>Affirms the funding approved under this decision (a) is subject to the availability of funding, and (b) shall be committed in annual tranches; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol>